263 related articles for article (PubMed ID: 19135568)
1. Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass.
Uras R; Orrù M; Etzi R; Peppi G; Marotto MF; Pilloni M; Zedda P; Lello S; Melis GB; Paoletti AM
Contraception; 2009 Feb; 79(2):117-21. PubMed ID: 19135568
[TBL] [Abstract][Full Text] [Related]
2. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study.
Fruzzetti F; Lello S; Lazzarini V; Fratta S; Orrù M; Sorge R; Minerba L; Ricci C; Genazzani AR; Melis GB; Paoletti AM
Contraception; 2007 Mar; 75(3):199-203. PubMed ID: 17303489
[TBL] [Abstract][Full Text] [Related]
3. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
[TBL] [Abstract][Full Text] [Related]
4. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
Fruzzetti F; Lazzarini V; Ricci C; Quirici B; Gambacciani M; Paoletti AM; Genazzani AR
Contraception; 2007 Sep; 76(3):190-4. PubMed ID: 17707715
[TBL] [Abstract][Full Text] [Related]
5. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
Winkler UH; Röhm P; Höschen K
Contraception; 2010 May; 81(5):391-400. PubMed ID: 20399945
[TBL] [Abstract][Full Text] [Related]
6. Effects of two different oral contraceptives on total body water: a randomized study.
Machado RB; Tachotti F; Cavenague G; Maia E
Contraception; 2006 Apr; 73(4):344-7. PubMed ID: 16531163
[TBL] [Abstract][Full Text] [Related]
7. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
8. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial.
Cagnacci A; Ferrari S; Tirelli A; Zanin R; Volpe A
Contraception; 2009 Feb; 79(2):111-6. PubMed ID: 19135567
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Terlinden R; Uragg H; Göhler K; Kneip C
Contraception; 2006 Sep; 74(3):239-44. PubMed ID: 16904418
[TBL] [Abstract][Full Text] [Related]
10. Influence of gender and body composition on hydration and body water spaces.
Ritz P; Vol S; Berrut G; Tack I; Arnaud MJ; Tichet J
Clin Nutr; 2008 Oct; 27(5):740-6. PubMed ID: 18774628
[TBL] [Abstract][Full Text] [Related]
11. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
Schramm G; Heckes B
Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
[TBL] [Abstract][Full Text] [Related]
12. A prospective open-label study to evaluate the effects of the oral contraceptive Harmonet (gestodene75/EE20) on body fat.
de Melo NR; Aldrighi JM; Faggion D; Reyes VR; Souza JB; Fernandes CE; Larson E
Contraception; 2004 Jul; 70(1):65-71. PubMed ID: 15208055
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
Zahradnik HP; Hanjalic-Beck A
Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women.
Schramm GA; Schrah G
Contraception; 2011 Oct; 84(4):390-401. PubMed ID: 21920195
[TBL] [Abstract][Full Text] [Related]
15. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles.
Rabe T; Hartschuh E; Wahlstrom T; Höschen K; König S
Contraception; 2010 Oct; 82(4):358-65. PubMed ID: 20851230
[TBL] [Abstract][Full Text] [Related]
16. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
[TBL] [Abstract][Full Text] [Related]
17. Body composition during normal pregnancy: reference ranges.
Larciprete G; Valensise H; Vasapollo B; Altomare F; Sorge R; Casalino B; De Lorenzo A; Arduini D
Acta Diabetol; 2003 Oct; 40 Suppl 1():S225-32. PubMed ID: 14618479
[TBL] [Abstract][Full Text] [Related]
18. Body water distribution in severe obesity and its assessment from eight-polar bioelectrical impedance analysis.
Sartorio A; Malavolti M; Agosti F; Marinone PG; Caiti O; Battistini N; Bedogni G
Eur J Clin Nutr; 2005 Feb; 59(2):155-60. PubMed ID: 15340370
[TBL] [Abstract][Full Text] [Related]
19. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
[TBL] [Abstract][Full Text] [Related]
20. Effect of subclinical hypothyroidism on body fluid compartments.
De Lorenzo A; Andreoli A; Fusco A; Magnani A; D'Orazio N; Bertoli A
Horm Metab Res; 2000 Sep; 32(9):359-63. PubMed ID: 11014384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
